The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilar Drug Market Research Report 2025
Synopsis
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
The global Biosimilar Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
In China, Biosimilar Drug key players include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, etc. Global top three manufacturers hold a share over 70%.
East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.
In terms of product, Tablets is the largest segment, with a share over 65%. And in terms of application, the largest application is Ankylosing Spondylitis, followed by Rheumatoid Arthrtis, Tumor, Cardiovascular, etc.
This report aims to provide a comprehensive presentation of the global market for Biosimilar Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Drug.
Report Scope
The Biosimilar Drug market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CP Guojian Pharma
Biotech Pharma
Celgen Pharma
Henlius
Amgen
Eli Lilly
Sandoz
Changchun High Tech
Innovent
Segment by Type
Injection
Tablets
Other Types
Segment by Application
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
The global Biosimilar Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
In China, Biosimilar Drug key players include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, etc. Global top three manufacturers hold a share over 70%.
East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.
In terms of product, Tablets is the largest segment, with a share over 65%. And in terms of application, the largest application is Ankylosing Spondylitis, followed by Rheumatoid Arthrtis, Tumor, Cardiovascular, etc.
This report aims to provide a comprehensive presentation of the global market for Biosimilar Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Drug.
Report Scope
The Biosimilar Drug market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CP Guojian Pharma
Biotech Pharma
Celgen Pharma
Henlius
Amgen
Eli Lilly
Sandoz
Changchun High Tech
Innovent
Segment by Type
Injection
Tablets
Other Types
Segment by Application
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Biosimilar Drug Market Overview
1.1 Product Overview and Scope of Biosimilar Drug
1.2 Biosimilar Drug Segment by Type
1.2.1 Global Biosimilar Drug Market Value Comparison by Type (2024-2030)
1.2.2 Injection
1.2.3 Tablets
1.2.4 Other Types
1.3 Biosimilar Drug Segment by Application
1.3.1 Global Biosimilar Drug Market Value by Application: (2024-2030)
1.3.2 Ankylosing Spondylitis
1.3.3 Tumor
1.3.4 Rheumatoid Arthrtis
1.3.5 Cardiovascular
1.3.6 Other Application
1.4 Global Biosimilar Drug Market Size Estimates and Forecasts
1.4.1 Global Biosimilar Drug Revenue 2019-2030
1.4.2 Global Biosimilar Drug Sales 2019-2030
1.4.3 Global Biosimilar Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Biosimilar Drug Market Competition by Manufacturers
2.1 Global Biosimilar Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Biosimilar Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Biosimilar Drug Average Price by Manufacturers (2019-2024)
2.4 Global Biosimilar Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilar Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilar Drug, Product Type & Application
2.7 Biosimilar Drug Market Competitive Situation and Trends
2.7.1 Biosimilar Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilar Drug Players Market Share by Revenue
2.7.3 Global Biosimilar Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilar Drug Retrospective Market Scenario by Region
3.1 Global Biosimilar Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Biosimilar Drug Global Biosimilar Drug Sales by Region: 2019-2030
3.2.1 Global Biosimilar Drug Sales by Region: 2019-2024
3.2.2 Global Biosimilar Drug Sales by Region: 2025-2030
3.3 Global Biosimilar Drug Global Biosimilar Drug Revenue by Region: 2019-2030
3.3.1 Global Biosimilar Drug Revenue by Region: 2019-2024
3.3.2 Global Biosimilar Drug Revenue by Region: 2025-2030
3.4 North America Biosimilar Drug Market Facts & Figures by Country
3.4.1 North America Biosimilar Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Biosimilar Drug Sales by Country (2019-2030)
3.4.3 North America Biosimilar Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Biosimilar Drug Market Facts & Figures by Country
3.5.1 Europe Biosimilar Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Biosimilar Drug Sales by Country (2019-2030)
3.5.3 Europe Biosimilar Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilar Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilar Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Biosimilar Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Biosimilar Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biosimilar Drug Market Facts & Figures by Country
3.7.1 Latin America Biosimilar Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Biosimilar Drug Sales by Country (2019-2030)
3.7.3 Latin America Biosimilar Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilar Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilar Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Biosimilar Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Biosimilar Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilar Drug Sales by Type (2019-2030)
4.1.1 Global Biosimilar Drug Sales by Type (2019-2024)
4.1.2 Global Biosimilar Drug Sales by Type (2025-2030)
4.1.3 Global Biosimilar Drug Sales Market Share by Type (2019-2030)
4.2 Global Biosimilar Drug Revenue by Type (2019-2030)
4.2.1 Global Biosimilar Drug Revenue by Type (2019-2024)
4.2.2 Global Biosimilar Drug Revenue by Type (2025-2030)
4.2.3 Global Biosimilar Drug Revenue Market Share by Type (2019-2030)
4.3 Global Biosimilar Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Biosimilar Drug Sales by Application (2019-2030)
5.1.1 Global Biosimilar Drug Sales by Application (2019-2024)
5.1.2 Global Biosimilar Drug Sales by Application (2025-2030)
5.1.3 Global Biosimilar Drug Sales Market Share by Application (2019-2030)
5.2 Global Biosimilar Drug Revenue by Application (2019-2030)
5.2.1 Global Biosimilar Drug Revenue by Application (2019-2024)
5.2.2 Global Biosimilar Drug Revenue by Application (2025-2030)
5.2.3 Global Biosimilar Drug Revenue Market Share by Application (2019-2030)
5.3 Global Biosimilar Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 CP Guojian Pharma
6.1.1 CP Guojian Pharma Corporation Information
6.1.2 CP Guojian Pharma Description and Business Overview
6.1.3 CP Guojian Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CP Guojian Pharma Biosimilar Drug Product Portfolio
6.1.5 CP Guojian Pharma Recent Developments/Updates
6.2 Biotech Pharma
6.2.1 Biotech Pharma Corporation Information
6.2.2 Biotech Pharma Description and Business Overview
6.2.3 Biotech Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Biotech Pharma Biosimilar Drug Product Portfolio
6.2.5 Biotech Pharma Recent Developments/Updates
6.3 Celgen Pharma
6.3.1 Celgen Pharma Corporation Information
6.3.2 Celgen Pharma Description and Business Overview
6.3.3 Celgen Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Celgen Pharma Biosimilar Drug Product Portfolio
6.3.5 Celgen Pharma Recent Developments/Updates
6.4 Henlius
6.4.1 Henlius Corporation Information
6.4.2 Henlius Description and Business Overview
6.4.3 Henlius Biosimilar Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Henlius Biosimilar Drug Product Portfolio
6.4.5 Henlius Recent Developments/Updates
6.5 Amgen
6.5.1 Amgen Corporation Information
6.5.2 Amgen Description and Business Overview
6.5.3 Amgen Biosimilar Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Amgen Biosimilar Drug Product Portfolio
6.5.5 Amgen Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Biosimilar Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Eli Lilly Biosimilar Drug Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Sandoz
6.6.1 Sandoz Corporation Information
6.6.2 Sandoz Description and Business Overview
6.6.3 Sandoz Biosimilar Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sandoz Biosimilar Drug Product Portfolio
6.7.5 Sandoz Recent Developments/Updates
6.8 Changchun High Tech
6.8.1 Changchun High Tech Corporation Information
6.8.2 Changchun High Tech Description and Business Overview
6.8.3 Changchun High Tech Biosimilar Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Changchun High Tech Biosimilar Drug Product Portfolio
6.8.5 Changchun High Tech Recent Developments/Updates
6.9 Innovent
6.9.1 Innovent Corporation Information
6.9.2 Innovent Description and Business Overview
6.9.3 Innovent Biosimilar Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Innovent Biosimilar Drug Product Portfolio
6.9.5 Innovent Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilar Drug Industry Chain Analysis
7.2 Biosimilar Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilar Drug Production Mode & Process
7.4 Biosimilar Drug Sales and Marketing
7.4.1 Biosimilar Drug Sales Channels
7.4.2 Biosimilar Drug Distributors
7.5 Biosimilar Drug Customers
8 Biosimilar Drug Market Dynamics
8.1 Biosimilar Drug Industry Trends
8.2 Biosimilar Drug Market Drivers
8.3 Biosimilar Drug Market Challenges
8.4 Biosimilar Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
